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Canine parvovirus (CPV) was first isolated at 1978 in the USA. Analysis of CPV isolates by monoclonal 
antibodies and restriction enzymes have shown that after the first emergence of CPV (CPV-2) it evolved 
to give rise to new antigenic types, which were designated CPV types 2a, 2b and 2c. These new types 
have replaced the original CPV type 2, although the proportions of each of the new antigenic types vary 
in different countries. In China, CPV infections were first observed in 1982, however, there has been no 
information concerning the antigenic types of CPV prevailing in China now. In this study, we designed a 
PCR assay to type canine parvovirus strains in fecal samples collected from symptomatic dogs from 
2006 to 2009. Our data showed that the CPV prevalent strain is mostly 2b, the proportion of CPV-2a is 
very low, no CPV-2c and CPV-2 were observed. 
 





Canine parvovirus (CPV) was first identified in 1978 in the 
USA (Appel et al., 1979) and was designated CPV type 2 
(CPV-2) to distinguish it from a previously recognized 
parvovirus of dogs known as minute virus of canines 
(Binn et al., 1970). After its emergence, CPV-2 spread 
globally, and now CPV viruses are endemic in most 
populations of domestic and wild canids (Parrish et al., 
1988). Analysis of CPV isolates by monoclonal antibodies 
and restriction enzymes have shown that a new antigenic 
strain, designated CPV type 2a (CPV-2a), became 
widespread around 1979 and that it replaced the original 
strain during 1980 to 1981 in the USA (Parrish et al., 
1985). Later examination of canine isolates identified 
another antigenic variant, designated CPV type 2b (CPV-
2b) that emerged around 1984, and after 1986 replaced 
CPV-2a in many parts of the USA (Parrish et al., 1991). 
Now, CPV-2c has emerged first in Italy (Buonavoglia et 
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emergence and subsequent replacement by the new 
antigenic strains were also shown by antigenic analysis 
of isolates from Denmark, Germany, France, Spain, 
Japan, Australia, Italy and Africa although the proportions 
of CPV-2a, CPV-2b and CPV-2c strains differ ( Parrish et 
al.,1988; Mochizuki et al., 1993; Ybanez et al., 1995; 
Truyen et al., 1996; Buonavoglia et al., 2001, Steinel et 
al.,1998). In China, CPV infections were first observed as 
sporadic cases during 1982 ( Liang et al., unpublished 
data ). Subsequently, widespread outbreaks of canine 
haemorrhagic enteritis with high morbidity and mortality 
occurred over the whole country, although there has been 
no information concerning the antigenic types of CPV 
prevailing in China. In this study, we developed a poly-
merase chain reaction (PCR) assay to type CPV strains 
based on the genetic markers of the three antigenic variants 
and used this assay to characterize the CPV strains 
prevalent in China. 
 
 




Faecal specimens (n = 30) collected from vaccinated and un-
vaccinated diarrhoeic dogs from years 2006 to 2009 and tested 
positive to CPV-2 by commercial immune colloidal gold assay kit 





came from young dogs of 1 to 17 months. As negative controls, 2 
faecal samples from CPV-2 negative dogs were used, and CPV live 





The samples were homogenised (10%, w/v) in phosphate-buffered 
saline (PBS) and clarifed by high-speed centrifugation (8000×g for 
5 min). DNA preparation was carried out rapidly by boiling the 
supernatants for 10 min and subsequent chilling on ice. In order to 
remove the residual inhibitors of the polymerase activity, the DNA 
extracts were reduced to effective concentrations by diluting 1:10 in 
distilled water prior to PCR amplifications (Decaro et al., 2005). 
 
 
Primers for PCR 
 
The sequences of all PCR primers were designed according to the 
VP2 capsid genes from published nucleotide sequences of CPV-2, 
2a, 2b and 2c (Accession No. AY380577, DQ340434, DQ025992, 
AB054223). Primer A, which detects the mutual upstream sequence 
of VP2 gene, the forward primer (5'-GGA TGGGTGGAAATC 
ACAGC-3') and reverse primer (5'-ATAACC AACTCAGCTGGTC-3') 
located, respectively at 2954-2973 and 3780-3799 yielded a 815 bp 
product. Primer B (forward primer 5'-TCCAGAAGGAGATTGG 
ATTC-3' and reverse primer 5'-TTCTAGGTGCTAGTTGAGATT-3'), 
which for amplification the downstream sequence of VP2 gene, 
respectively located at 4012 - 4031 and 4509 - 4529 yield a 518 bp 
product, and the product containing an mbo II site for specific 





The PCR assay was performed as previously described (Kong and 
Zhang 2003) with some modifications in the MgCl2 final 
concentration. The most sensitive and reliable concentration of 
MgCl2 was found to be 1.5 mM for all the primers. Briefly, the PCR 
was performed in a thermal cycler (Applied Biosystem, 2720 
thermal cycler) for 30 cycles, each consisting of denaturation at 
94°C for 30 s, annealing at 52°C for 2 min and polymerization at 
72°C for 1 min. PCR products were electrophoresed on 1.2% 
agarose gels, gels were stained with ethidium bromide and then 
visualized with ultraviolet light.  
 
 
Restriction enzyme analysis of the PCR products (518 bp 
amplicon) 
 
The restriction enzyme Mbo II was found to recognize selectively 
the sequence GAAGA at 4060-4064 bp for CPV-2c. Then, the 
amplicons (10 l) obtained by PCR amplification with primer B were 
digested at 37°C for 3 h with 5 units Mbo II restriction endonuclease 
as recommended by the manufacture (TAKARA, Da Lian, China), 






Amplocons were sequenced, using an ABI prism 3730-Perkin Elmer 
automated sequencer, either directly or after being cloned using the 
T/A clone PCR product cloning Kit (Takara, DaLian, China). 
Sequencing was carried out twice on both strands using Big 
Dye terminator v3.1 as recommended by the manufacturer. 








Two DNA bands of the expected size (815, 518 bp), cor-
responding to the partial amplification of the VP2 gene, 
was observed by gel electrophoresis in 23 of the 30 field 
samples suspected of hanging CPV. Two bands of the 
same size were used as positive control. No amplified 
products were obtained from faecal samples of clinically 
healthy dogs used as negative controls. 
 
 
Genotyping the samples: RFLP and sequence 
 
In order to test the presence of CPV-2c in the samples, 
we performed a RFLP analysis using the Mbo II enzyme 
as reported by Buonavoglia et al. (2001) Our analysis 
indicated that no type 2c RFLP pattern were observed 
(Table 1). So, all the samples were sent to sequence 
analysis, and the results revealed that all the 23 samples 
were presented as CPV-2a and CPV-2b type. 
The sequencing of the 23 samples revealed that only 
2/23 presented an AAT codon at position 426 of the VP2 
protein, characteristic of CPV-2a, while other 21 samples 
presented a GAT codon at the same position of VP2 
protein, characteristic of CPV-2b (Table 2). 
The VP2 sequence alignment of the Chinese CPV-2a 
indicated that the strains Ch-NJ1 and Ch-NJ3 exhibited 
100% nucleotide identity with the CPV-2a from China 
(cpv/nj01/06) and 99.6% identical to Taiwanese isolate 
(Taiwan 9), it is worth noting that the two strains came 
from the same place, NanJiang, the capital of JiangSu 
province. In comparison with the Japanese CPV-2b (HNI-
2-13), the Ch-YZ1, Ch-AH1, Ch-YZ2, Ch-YZ3, Ch-ZhJ 
and Ch-ZhJ2 had 99.4% (ten differences), Ch-BJ, Ch-XZ, 
Ch-AH2 and Ch-ZJ had 99.2% (thirteen differences), the 
Ch-HA, Ch-CZ, Ch-SQ, Ch-ZhJ2, Ch-JX had 99.1% (fifteen 
differences), and others had 98.9% (eighteen differences) 
nucleotide identity. The Ch-ZJ, Ch-CZ, Ch-BJ, Ch-YZ3 
showed two amino acid changes (Phe-137 to Leu, Thr-
314 to Ala), Phe-267 to Tyr were observed in Ch-LYG, 
Ch-NT2, Ch-SQ and Ch-TZ, Thr-440 to Ala was observed 
in Ch-HA and Ch-AH2, the other nucleotides changes 





As surprising as the emergence and sudden dispersion 
that CPV-2 experimented in the 1970s, were the changes, 
including an extended host range that the virus further 
underwent in a few years (Shackelton et al., 2005; 
Truyen, 2006). The great virus variability, in part con-
sequence of its high mutation rate similar to the one 
observed in fast evolving RNA viruses (Shackelton et al., 
2005) has raised concern about its potential negative 
impact on the health of domestic dogs and wildlife species. 




Table 1. Chinese CPV stain analysed in the present study. 
 
Sample Vaccines Course Procedure Race Cpv 
Ch-YZ1 Complete Died YangZhou Undefined 2b 
Ch-NJ1 Incomplete Recovered NanJing Pekinese 2a 
Ch-AH1 Complete Recovered AnHui Poodle 2b 
Ch-YZ2 Complete NA YangZhou Undefined 2b 
Ch-NT1 Complete Recovered NanTong ChowChow 2b 
Ch-TZ NA NA TaiZhou German shepherd 2b 
Ch-NJ2 Complete Recovered NanJing Collie 2b 
Ch-YC Complete Died YanCheng Collie 2b 
Ch-YZ3 Complete Recovered YangZhou Golden retriever 2b 
Ch-NJ3 Complete Died NanJing Shar Pei 2a 
Ch-BJ Complete Recovered BeiJing Saint Bernard 2b 
Ch-XZ None Recovered XiZhang Tibetan Mastiff 2b 
Ch-LYG Incomplete NA LianYungang ChowChow 2b 
Ch-NT2 Complete Recovered NanTong Poodle 2b 
Ch-AH2 Complete Recover AnHui Bull dog 2b 
Ch-SH Incomplete Died ShangHai German shepherd 2b 
Ch-JX Complete Recovered JiaXing Saint Bernard 2b 
Ch-ZJ Complete Recovered ZhenJiang Bull dog 2b 
Ch-ZhJ Complete NA ZhengJiang Collie 2b 
Ch-HA NA Died HuaiAn Labrador retriever 2b 
Ch-CZ Complete Recovered ChangZhou Great Pyrenees 2b 
Ch-SQ Incomplete Recovered SuQian Pekinese 2b 
Ch-ZhJ2 Complete Died ZhengJiang Chihuahua 2b 
 
Faecal samples were collected from vaccinated and unvaccinated puppies with haemorrhagic enteritis. Dogs were assisted in 
veterinary clinics located in different Chinese departments. Some dogs presented a complete vaccination plan; others had not received 
the complete series (at least three doses) of vaccines and other did not receive any vaccines at all. Genotype characterization was 




Although the new variant CPV-2c had been detected 
first in Italy (Buonavoglia et al., 2001) , subsequent 
occurrence in other European countries and South 
America (Schacketlton et al., 2005; Decaro et al., 2006, 
2007; Ruben et al., 2007), no CPV-2c was detected in the 
present study. More striking than the simple presence is 
the high frequency (21 out of 23) that CPV-2b achieved in 
China. This fact, together with its occurrence in different 
localities (Table 1) is indicative that type 2b is currently 
the prevalent field CPV circulating in the country. 
Although we know that CPV appeared in China around 
1982 (Liang et al., unpublished data), there is no data 
about CPV genotypes existing in the country in previous 
years that allow the comparative analysis of the evolution 
of CPV variants over time. We can hypothesize that the 
Chinese CPV-2b replaced previous circulating CPV, as 
occurred in USA. This result, together with our own 
findings, indicates that the spreading ability of the type 2b 
is associated with an important replacement capacity that 
could eventually lead to the elimination of CPV-2a. 
The results of the investigation of the 23 CPV strains 
indicate that in the area examined the CPV-2b variant is 
more popular than the CPV-2a variant. A similar epide-
miological pattern has been reported in the USA and UK 
(Ybañez et al., 1995; Greenwood et al., 1996; Davies, 
2008); in Germany and in Spain the two variants appear 
to be distributed about equally; in contrast, CPV-2a 
appears to be more common in Australia. The reasons for 
the different worldwide distribution of the CPV variants 
are unclear, and they will probably remain obscure until 
the mechanisms whereby CPV has evolved are defined. 
Beside the CPV-2b, we also identified the Chinese samples, 
two CPV-2a strains characterized by the presence of an 
Asn426 residue, which had 100% identity with the 
reported sequence of nj01/06 strain in China. Probably, 
the CPV-2a strain represents a relic of the original types 
that were predominant in China before CPV-2b appearance, 
furthermore, this speculation is in accordance with the 
trend circulating in neighbouring countries as Japan (Doki 
et al., 2006). To our knowledge, no reports about CPV-2c 
until now in Asia except Vietnam (Nakamura et al., 2004). 
So, it is evident that further studies will be needed to 
obtain additional evidence on the CPV behaviour in China 
in the next years.  




Table 2. Amino acid differences in whole VP2 sequences of Chinese strains of CPV (type 2a: Ch-NT1 and Ch-NJ3, type 2b: others) with 
CPV-2a from Japan (V154, AB054217), CPV-2b from Japan (LCPV V204, AB054221). 
 
Place of amino acid site 
Strains 
87 93 103 137 267 297 300 314 323 426 440 562 564 
Gene type 
CPV-b M N A F F S A T N N T V G CPV-2 
V154 L N A F F A G T N N T V G CPV-2a 
LCPV-V204 L N A F F A G T N D T V G CPV-2b 
Ch-YZ1 L N A F F A G T N D T V G CPV-2b 
Ch-NJ1 L N A F F A G T N N T V G CPV-2a 
Ch-AH1 L N A F F A G T N D T V G CPV-2b 
Ch-YZ2 L N A F F A G T N D T V G CPV-2b 
Ch-NT1 L N A F F A G T N D T V G CPV-2b 
Ch-TZ L N A F Y A G T N D T V G CPV-2b 
Ch-NJ2 L N A F F A G T N D T V G CPV-2b 
Ch-YC L N A F F A G T N D T V G CPV-2b 
Ch-YZ3 L N A L F A G A N D T V G CPV-2b 
Ch-NJ3 L N A F F A G T N N T V G CPV-2a 
Ch-BJ L N A L F A G A N D T V G CPV-2b 
Ch-XZ L N A F F A G T N D T V G CPV-2b 
Ch-LYG L N A F Y A G T N D T V G CPV-2b 
Ch-NT2 L N A F Y A G T N D T V G CPV-2b 
Ch-AH2 L N A F F A G T N D A V G CPV-2b 
Ch-SH L N A F F A G T N D T V G CPV-2b 
Ch-JX L N A F F A G T N D T V G CPV-2b 
Ch-ZJ L N A L F A G A N D T V G CPV-2b 
Ch-ZhJ L N A F F A G T N D T V G CPV-2b 
Ch-HA L N A F F A G T N D A V G CPV-2b 
Ch-CZ L N A L F A G A N D T V G CPV-2b 
Ch-SQ L N A F Y A G T N D T V G CPV-2b 
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